1. To which molecular target do sulfonylureas bind to produce their insulin-secretory effect?
A) The Kir6.2 pore-forming subunit of the ATP-sensitive potassium (KATP) channel
B) The voltage-gated calcium channel of the beta cell plasma membrane
C) The SUR1 (sulfonylurea receptor 1) regulatory subunit of the KATP channel
D) The glucagon-like peptide-1 (GLP-1) receptor on the beta cell surface
E) The sodium-glucose cotransporter-2 (SGLT-2) on the proximal tubule
ANSWER: C
Rationale:
Sulfonylureas bind the SUR1 regulatory subunit of the KATP channel, stabilizing the channel in its closed state and depolarizing the beta cell to trigger insulin secretion.
Option A: Option A is incorrect because the binding target is the regulatory SUR1 subunit, not the Kir6.2 pore-forming subunit, which forms the potassium-conducting pore but is not the drug-binding site.
Option B: Option B is incorrect because sulfonylureas do not bind voltage-gated calcium channels; calcium entry follows the membrane depolarization produced by channel closure.
Option D: Option D is incorrect because the GLP-1 receptor is the target of incretin mimetics, not sulfonylureas.
Option E: Option E is incorrect because SGLT-2 is the target of the gliflozin class, which is unrelated to the sulfonylurea mechanism.
2. The beta cell KATP channel is a hetero-octamer. Which statement correctly distinguishes the roles of its two subunit types?
A) Kir6.2 forms the potassium-conducting pore, while SUR1 is the regulatory subunit that senses nucleotides and binds sulfonylureas
B) SUR1 forms the potassium-conducting pore, while Kir6.2 is the regulatory subunit that binds sulfonylureas
C) Both Kir6.2 and SUR1 are pore-forming subunits, and neither binds sulfonylureas
D) Kir6.2 binds sulfonylureas directly, while SUR1 conducts the potassium current
E) SUR1 is a voltage sensor only, while Kir6.2 binds both ATP and sulfonylureas
ANSWER: A
Rationale:
The KATP channel is assembled from four Kir6.2 (inward-rectifier potassium channel 6.2) pore-forming subunits and four SUR1 regulatory subunits; SUR1 contains the nucleotide-binding domains that sense the ATP/ADP ratio and the drug-binding site for sulfonylureas.
Option B: Option B inverts the roles: Kir6.2, not SUR1, forms the pore.
Option C: Option C is incorrect because the two subunits have distinct functions—Kir6.2 is pore-forming and SUR1 is regulatory and drug-binding—rather than both being pores.
Option D: Option D inverts the drug-binding and conducting roles.
Option E: Option E is incorrect because SUR1 is not merely a voltage sensor and Kir6.2 is not the sulfonylurea-binding subunit.
3. Which sulfonylurea is metabolized to inactive metabolites and is therefore the preferred agent of its class in chronic kidney disease (CKD)?
A) Glyburide
B) Chlorpropamide
C) Tolbutamide
D) Glipizide
E) Tolazamide
ANSWER: D
Rationale:
Glipizide undergoes extensive hepatic metabolism by CYP2C9 (cytochrome P450 2C9) to inactive metabolites, so it does not accumulate as renal clearance declines, making it the preferred sulfonylurea in CKD.
Option A: Option A is incorrect because glyburide is metabolized to weakly active metabolites that accumulate in CKD, making it the most dangerous sulfonylurea in renal impairment.
Option B: Option B is incorrect because chlorpropamide is a first-generation agent with a very long half-life and high hypoglycemia risk, not the preferred CKD agent.
Option C: Option C is incorrect because tolbutamide is a first-generation agent not preferred in CKD.
Option E: Option E is incorrect because tolazamide is a first-generation agent with an unfavorable profile and is not the preferred choice in renal impairment.
4. Glimepiride is metabolized by CYP2C9 to a metabolite designated M1. Which statement about M1 is correct?
A) M1 is pharmacologically inactive and is excreted entirely in bile
B) M1 is an active metabolite with approximately one-third the potency of glimepiride and is renally excreted, requiring dose reduction in CKD
C) M1 is more potent than the parent glimepiride and accumulates only in hepatic failure
D) M1 is an inactive metabolite identical to the metabolites produced by glyburide
E) M1 is a reactive intermediate that causes the cardiovascular risk attributed to sulfonylureas
ANSWER: B
Rationale:
Glimepiride is metabolized by CYP2C9 to an active M1 metabolite that has roughly one-third the potency of the parent drug; M1 is renally excreted, so dose reduction is required in CKD, though glimepiride is generally better tolerated in moderate renal impairment than glyburide.
Option A: Option A is incorrect because M1 is active, not inactive, and is renally rather than purely biliary excreted.
Option C: Option C is incorrect because M1 is less potent than the parent glimepiride, not more potent, and its relevance is to renal rather than hepatic accumulation.
Option D: Option D is incorrect because M1 is an active metabolite distinct from the weakly active glyburide metabolites.
Option E: Option E is incorrect because M1 is not a reactive intermediate responsible for cardiovascular risk; the cardiovascular controversy relates to KATP channel effects in non-beta-cell tissue, not the M1 metabolite.
5. How does the binding site of repaglinide relate to the binding site of the sulfonylureas?
A) Repaglinide and sulfonylureas bind the identical site on SUR1 with identical kinetics
B) Repaglinide binds Kir6.2 while sulfonylureas bind SUR1, so they act on different subunits
C) Repaglinide binds a site on the GLP-1 receptor distinct from the sulfonylurea KATP site
D) Repaglinide binds SUR1 but with slower association and dissociation kinetics than sulfonylureas
E) Repaglinide binds a distinct site on SUR1 (the benzamido site) with faster association and dissociation kinetics than the sulfonylurea site
ANSWER: E
Rationale:
Repaglinide binds a distinct site on the SUR1 subunit, the benzamido site, separate from the classic sulfonylurea binding site though located on the same subunit, and this site has faster association and dissociation kinetics, producing a shorter duration of action.
Option A: Option A is incorrect because the sites are distinct and the kinetics differ.
Option B: Option B is incorrect because repaglinide binds SUR1, not Kir6.2; both drug classes act through SUR1.
Option C: Option C is incorrect because repaglinide does not act on the GLP-1 receptor; it acts on the KATP channel via SUR1.
Option D: Option D inverts the kinetics: repaglinide's benzamido site has faster, not slower, association and dissociation than the sulfonylurea site.
6. The two available meglitinides differ in their chemical class. Which pairing is correct?
A) Repaglinide is a benzoic acid derivative; nateglinide is a phenylalanine derivative
B) Repaglinide is a phenylalanine derivative; nateglinide is a benzoic acid derivative
C) Both repaglinide and nateglinide are sulfonylurea derivatives
D) Repaglinide is a biguanide; nateglinide is a benzoic acid derivative
E) Both repaglinide and nateglinide are phenylalanine derivatives
ANSWER: A
Rationale:
Repaglinide is a benzoic acid derivative, and nateglinide is a phenylalanine derivative; both are non-sulfonylurea secretagogues acting at SUR1.
Option B: Option B inverts the two chemical classes.
Option C: Option C is incorrect because meglitinides are explicitly non-sulfonylurea secretagogues, not sulfonylurea derivatives.
Option D: Option D is incorrect because repaglinide is a benzoic acid derivative, not a biguanide; the biguanide class is metformin.
Option E: Option E is incorrect because only nateglinide is a phenylalanine derivative; repaglinide is a benzoic acid derivative.
7. Which statement correctly distinguishes the metabolism of the two meglitinides?
A) Both repaglinide and nateglinide are eliminated unchanged by the kidney without hepatic metabolism
B) Repaglinide is metabolized by CYP2C9, while nateglinide is metabolized by CYP3A4 and CYP2C8
C) Repaglinide is metabolized by CYP3A4 and CYP2C8 with predominantly biliary elimination, while nateglinide is metabolized by CYP2C9
D) Neither agent is metabolized by cytochrome P450 enzymes; both are conjugated directly
E) Repaglinide is metabolized solely by monoamine oxidase, while nateglinide is metabolized by CYP2C9
ANSWER: C
Rationale:
Repaglinide is metabolized by CYP3A4 (cytochrome P450 3A4) and CYP2C8 (cytochrome P450 2C8) to inactive metabolites eliminated predominantly in bile and feces, while nateglinide is metabolized by CYP2C9 (cytochrome P450 2C9).
Option A: Option A is incorrect because both agents undergo hepatic CYP metabolism rather than unchanged renal elimination.
Option B: Option B inverts the enzyme assignments for the two drugs.
Option D: Option D is incorrect because both are metabolized by cytochrome P450 enzymes, not by direct conjugation alone.
Option E: Option E is incorrect because repaglinide is metabolized by CYP3A4 and CYP2C8, not by monoamine oxidase.
8. In metformin's AMPK-dependent hepatic mechanism, which sequence of events correctly links complex I inhibition to reduced gluconeogenesis?
A) Complex I inhibition lowers the AMP/ATP ratio, inactivating AMPK and increasing PEPCK transcription
B) Complex I inhibition raises the AMP/ATP ratio, activating AMPK, which reduces transcription of the gluconeogenic enzymes PEPCK and G6Pase
C) Complex I activation raises ATP, which directly phosphorylates PEPCK to inactivate it
D) Complex I inhibition activates AMPK, which increases transcription of PEPCK and G6Pase to clear glucose
E) Complex I inhibition raises the AMP/ATP ratio, but AMPK then stimulates gluconeogenesis to restore energy
ANSWER: B
Rationale:
Metformin inhibits mitochondrial complex I, reducing ATP synthesis and raising the AMP/ATP ratio; this activates AMP-activated protein kinase (AMPK), which inactivates the co-activator TORC2 and thereby reduces transcription of PEPCK (phosphoenolpyruvate carboxykinase) and G6Pase (glucose-6-phosphatase), lowering hepatic glucose output.
Option A: Option A inverts the direction of the AMP/ATP change and the effect on gluconeogenic transcription.
Option C: Option C is incorrect because metformin inhibits rather than activates complex I and does not lower glucose by ATP directly phosphorylating PEPCK.
Option D: Option D is incorrect because activated AMPK reduces, not increases, transcription of gluconeogenic enzymes.
Option E: Option E is incorrect because AMPK activation suppresses gluconeogenesis rather than stimulating it.
9. Metformin lowers hepatic glucose output partly through an AMPK-independent mechanism. Which description is correct?
A) It directly inhibits glucose-6-phosphatase enzyme activity without any change in cellular redox state
B) It activates AMPK more strongly, which is simply a higher-intensity version of the AMPK-dependent route
C) It increases hepatic glycogenolysis, depleting glucose stores before they can be released
D) Complex I inhibition raises the cytosolic NADH-to-NAD+ ratio, limiting conversion of lactate and glycerol into gluconeogenic substrate because those steps require NAD+
E) It blocks intestinal glucose absorption, reducing the substrate available for hepatic gluconeogenesis
ANSWER: D
Rationale:
The AMPK-independent mechanism arises because complex I inhibition reduces mitochondrial NADH oxidation, raising the cytosolic NADH-to-NAD+ ratio; gluconeogenesis from lactate (via lactate dehydrogenase) and from glycerol (via glycerol-3-phosphate dehydrogenase) requires NAD+, so the elevated ratio limits substrate flux into gluconeogenesis independently of AMPK.
Option A: Option A is incorrect because this mechanism depends on a redox change (the NADH/NAD+ shift), not direct enzyme inhibition without redox change.
Option B: Option B is incorrect because the defining feature is that it operates independently of AMPK, not as a stronger AMPK effect.
Option C: Option C is incorrect because the mechanism limits gluconeogenic substrate flux, not glycogenolysis.
Option E: Option E describes an intestinal effect of metformin that is separate from the AMPK-independent hepatic redox mechanism.
10. Which transporter pairing correctly distinguishes metformin's hepatic uptake from its renal elimination?
A) Hepatic uptake occurs via OCT1; renal tubular secretion occurs via OCT2 and MATE1/MATE2-K
B) Hepatic uptake occurs via OCT2; renal tubular secretion occurs via OCT1 and SGLT2
C) Hepatic uptake and renal secretion both occur exclusively via OCT1
D) Hepatic uptake occurs via P-glycoprotein; renal secretion occurs via OCT1
E) Hepatic uptake occurs via OCT2; renal secretion occurs via passive glomerular filtration only
ANSWER: A
Rationale:
Metformin enters hepatocytes via OCT1 (organic cation transporter 1) on the sinusoidal membrane, and it is secreted into the renal tubule via OCT2 (organic cation transporter 2) on the basolateral membrane and MATE1/MATE2-K (multidrug and toxin extrusion proteins) on the luminal membrane.
Option B: Option B inverts the hepatic and renal transporters and incorrectly invokes SGLT2.
Option C: Option C is incorrect because hepatic uptake (OCT1) and renal secretion (OCT2/MATE) use different transporters, not OCT1 exclusively.
Option D: Option D is incorrect because hepatic uptake is via OCT1, not P-glycoprotein.
Option E: Option E is incorrect because renal elimination involves active tubular secretion via OCT2 and MATE in addition to glomerular filtration, not filtration alone, and hepatic uptake is via OCT1 rather than OCT2.
11. Which statement correctly describes the eGFR (estimated glomerular filtration rate) thresholds governing metformin use?
A) Metformin is contraindicated below an eGFR of 60 and used at full dose only above 90 mL/min/1.73m2
B) Metformin is contraindicated below an eGFR of 45 and has no cautious-use range
C) Metformin may be used at full dose at any eGFR provided liver function is normal
D) Metformin is contraindicated below an eGFR of 15 and used at full dose above 30 mL/min/1.73m2
E) Metformin is contraindicated below an eGFR of 30, used with caution and reduced dose between 30 and 45, and used at full dose above 45 mL/min/1.73m2
ANSWER: E
Rationale:
Current FDA and ADA guidance contraindicates metformin below an eGFR of 30 mL/min/1.73m2, advises caution and reduced dosing between 30 and 45, and permits full dosing above 45.
Option A: Option A is incorrect because the contraindication threshold is an eGFR of 30, not 60, and full dosing is permitted above 45, not only above 90.
Option B: Option B is incorrect because the contraindication is below 30, and there is a defined cautious-use range of 30 to 45.
Option C: Option C is incorrect because renal function, not just liver function, governs the metformin contraindication.
Option D: Option D misstates both thresholds: the contraindication is below 30, not 15, and full dosing requires an eGFR above 45, not above 30.
12. What is the principal rationale for the extended-release (XR) formulation of metformin compared with the immediate-release (IR) formulation?
A) XR achieves higher peak plasma concentrations, increasing potency at lower doses
B) XR is renally excreted while IR is hepatically metabolized, improving safety in CKD
C) XR slows luminal drug release and reduces peak proximal intestinal drug concentrations, lowering the rate of gastrointestinal adverse effects
D) XR converts metformin into an active metabolite that IR cannot produce
E) XR eliminates the risk of lactic acidosis that is unique to the IR formulation
ANSWER: C
Rationale:
The XR (extended-release) formulation was developed primarily to reduce gastrointestinal adverse effects by slowing luminal drug release and reducing peak proximal intestinal drug concentrations, yielding roughly 30 to 40 percent lower rates of gastrointestinal intolerance than IR at equivalent doses.
Option A: Option A is incorrect because XR does not raise peak plasma concentrations; it lowers peak luminal concentrations.
Option B: Option B is incorrect because both formulations contain the same renally excreted drug; the formulations do not differ in metabolic route.
Option D: Option D is incorrect because metformin is not metabolized to an active metabolite by either formulation.
Option E: Option E is incorrect because lactic acidosis risk relates to drug and lactate accumulation in renal impairment and is not eliminated by the XR formulation.
13. What is the mechanistic basis of metformin-associated lactic acidosis (MALA)?
A) Metformin stimulates beta cell insulin secretion so strongly that lactate is generated by hypoglycemia-driven anaerobic metabolism
B) Metformin inhibits complex I in liver and kidney, impairing lactate clearance and raising circulating lactate, which becomes severe when metformin clearance is reduced or lactate production is increased
C) Metformin directly converts pyruvate to lactate in the bloodstream through an extracellular enzyme
D) Metformin causes lactic acidosis by inducing profound hypoglycemia identical to the sulfonylurea mechanism
E) Metformin acidifies the blood directly because it is a strong acid administered in gram quantities
ANSWER: B
Rationale:
Metformin inhibits complex I in hepatic and renal tissue, reducing lactate clearance and modestly raising circulating lactate even at therapeutic doses; lactic acidosis develops when this accumulation becomes severe, typically when metformin clearance is markedly reduced (severe renal impairment) or lactate production is increased (sepsis, shock, hepatic failure).
Option A: Option A is incorrect because metformin is not an insulin secretagogue and does not cause lactate accumulation through hypoglycemia.
Option C: Option C is incorrect because metformin does not convert pyruvate to lactate via an extracellular enzyme; the mechanism is impaired lactate clearance.
Option D: Option D is incorrect because metformin does not cause hypoglycemia as the sulfonylureas do, and MALA is not a hypoglycemia phenomenon.
Option E: Option E is incorrect because metformin does not acidify blood by acting as a strong acid; the acidosis results from lactate accumulation.
14. By what mechanism does long-term metformin therapy reduce vitamin B12 (cobalamin) levels?
A) It accelerates renal excretion of vitamin B12 by inhibiting tubular reabsorption
B) It destroys intrinsic factor in the gastric lumen, preventing B12 binding altogether
C) It competitively inhibits dihydrofolate reductase, depleting the active cofactor pool
D) It interferes with the calcium-dependent binding of the vitamin B12-intrinsic factor complex to its ileal receptor, an effect reversible with calcium supplementation
E) It increases hepatic storage of B12 so that circulating levels fall while total body stores rise
ANSWER: D
Rationale:
Metformin reduces ileal absorption of vitamin B12 by interfering with the calcium-dependent binding of the vitamin B12-intrinsic factor (IF) complex to its receptor in the terminal ileum; this effect is reversible with calcium supplementation.
Option A: Option A is incorrect because the mechanism is impaired ileal absorption, not accelerated renal excretion.
Option B: Option B is incorrect because metformin does not destroy intrinsic factor; it impairs the calcium-dependent receptor binding step.
Option C: Option C describes the mechanism of antifolate drugs, not metformin's effect on B12.
Option E: Option E is incorrect because metformin depletes B12 by impairing absorption, not by sequestering it in hepatic stores.
15. How do sulfonylureas and metformin differ in their effect on body weight?
A) Sulfonylureas typically cause weight gain of approximately 2 to 4 kg, whereas metformin is weight-neutral or produces modest weight reduction
B) Sulfonylureas are weight-neutral, whereas metformin reliably causes weight gain of 5 to 10 kg
C) Both classes cause equivalent and substantial weight gain through identical mechanisms
D) Sulfonylureas cause weight loss through appetite suppression, whereas metformin causes weight gain
E) Neither class has any measurable effect on body weight
ANSWER: A
Rationale:
Sulfonylureas predictably cause weight gain of approximately 2 to 4 kg over 6 to 12 months, driven by the insulin secretagogue mechanism (reversal of glycosuria, anabolic effect of elevated insulin, and defensive carbohydrate intake), whereas metformin is weight-neutral or produces modest weight reduction.
Option B: Option B inverts the two effects.
Option C: Option C is incorrect because the classes do not cause equivalent weight gain through identical mechanisms; metformin does not drive insulin-mediated weight gain.
Option D: Option D is incorrect because sulfonylureas cause weight gain rather than appetite-suppressing weight loss, and metformin does not cause weight gain.
Option E: Option E is incorrect because sulfonylureas have a clear weight-gain effect.
16. A clinician adds a second agent to metformin for a patient whose primary concern is avoiding hypoglycemia, and is weighing a sulfonylurea against a DPP-4 (dipeptidyl peptidase-4) inhibitor. Based on the cardiovascular outcome evidence comparing glimepiride with linagliptin, which conclusion best informs this decision?
A) The sulfonylurea should be chosen because it demonstrated superior cardiovascular outcomes over the DPP-4 inhibitor
B) The two agents are interchangeable because they showed identical hypoglycemia rates
C) The DPP-4 inhibitor should be avoided because it increased cardiovascular mortality relative to the sulfonylurea
D) The sulfonylurea should be chosen because it carried a lower hypoglycemia risk than the DPP-4 inhibitor
E) Cardiovascular outcomes were non-inferior between the two agents, but the sulfonylurea carried significantly higher hypoglycemia risk, favoring the DPP-4 inhibitor when minimizing hypoglycemia is the priority
ANSWER: E
Rationale:
The cardiovascular outcome trial comparing glimepiride with linagliptin showed non-inferior cardiovascular outcomes between the two agents but significantly higher hypoglycemia rates with the sulfonylurea; when the patient's priority is minimizing hypoglycemia, this evidence favors the DPP-4 inhibitor.
Option A: Option A is incorrect because the sulfonylurea was cardiovascular non-inferior, not superior.
Option B: Option B is incorrect because hypoglycemia rates were not identical; they were significantly higher with the sulfonylurea.
Option C: Option C is incorrect because the DPP-4 inhibitor did not increase cardiovascular mortality; outcomes were non-inferior.
Option D: Option D inverts the hypoglycemia finding: the sulfonylurea carried the higher, not lower, hypoglycemia risk.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.